Evidence map›Paper›PMID 40756372›Full record

Trial reportTheranostics2025

Secreted Clever-1 modulates T cell responses and impacts cancer immunotherapy efficacy.

Stuart Prince, Miro Viitala, Riikka Sjöroos, Ábris Á Bendes, Jenna H Rannikko, Daniel A Patten, Ilaria di Benedetto, Rita Turpin, Arno Ylitalo, Laura Tyni and 6 more

Abstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. CLEVER-1Frontiers in immunology · 2026
    Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Stuart PrinceMediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Miro ViitalaMediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Riikka SjöroosMediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Ábris Á BendesMediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Jenna H RannikkoMediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Daniel A PattenNational Institute for Health Research, Birmingham Biomedical Research Centre at University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Ilaria di BenedettoMediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Rita TurpinMediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Arno YlitaloMediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Laura TyniMediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Carlos R FigueiredoMediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Pia BoströmDepartment of Pathology, Turku University Hospital, Turku Finland.
Ilkka KoskivuoDepartment of Plastic and General Surgery, Turku University Hospital and University of Turku, Turku, Finland.
Tiina A SalminenStructural Bioinformatics Laboratory and InFLAMES flagship, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.
Shishir ShettyNational Institute for Health Research, Birmingham Biomedical Research Centre at University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Maija HollménMediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsImmunotherapyNeoplasmsT-LymphocytesAntibodies, Monoclonal, HumanizedFemaleHumansImmune Checkpoint InhibitorsLymphocyte ActivationAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsbexmarilimabcancerimmunotherapymacrophageMATINSstabilin-1

Identifiers

PMID40756372
PMCPMC12315809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.